Boehringer Ingelheim and Ablynx inked a deal worth almost $265 million to discover and develop new therapies for Alzheimer’s disease. The worldwide collaboration and license agreement will use Ablynx’ Nanobodies®, a novel class of therapeutic proteins.
In addition Boehringer Ingelheim will commence a joint research program with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture, and commercialization of any products resulting from the collaboration. The deal includes an upfront fee, development and commercial milestones., and sales-based royalties.